BASF, Colgate-Palmolive, Estée Lauder, and Unilever Among Keynote Speakers at 2020 Veeva Quality & Regulatory Global Summit
Veeva Systems (NYSE: VEEV) today announced the featured keynote speakers at 2020 Veeva Quality & Regulatory Global Summit. Leaders from the world’s top consumer goods, chemical, and cosmetics companies, including BASF, Colgate-Palmolive, Estée Lauder, L’Oréal, Pierre Fabre, Procter & Gamble, Reckitt Benckiser, and Unilever will showcase how they’re modernizing quality management processes and transforming regulatory operations.
The virtual event will take place from October 19-22 and include 20 presentations and panel discussions with more than 30 quality, regulatory, legal, and IT experts from North America and Europe. Visionaries from regulated industries will share strategies and tactics to improve quality, regulatory, and marketing processes across the product lifecycle, including:
- Estée Lauder, Procter & Gamble, and SEQENS discussing strategies they implemented across IT, quality, and regulatory operations to achieve greater resilience and maintain compliance.
- BASF and L’Oréal sharing how they respond to changing market conditions while remaining competitive and compliant across quality, regulatory, and product and process management.
- IFF, L’Occitane, and Procter & Gamble highlighting how consumer demand for safe, sustainable products has brought industries and supply chains closer together to offer better management of advertising claims, compliance, traceability, and circular economies.
“We look forward to hosting a diverse group of industry thought leaders sharing their expertise with their peers across the consumer goods, chemical, and cosmetics industries,” said Frank Defesche, general manager and senior vice president at Veeva. “Attendees will gain new insights to align business and IT priorities and modernize quality management processes, transform regulatory operations, and streamline global management of advertising claims.”
In addition to keynote sessions, participants can choose from 14 sessions in concurrent, customer-led tracks for quality, regulatory, advertising claims management, and IT. Tracks will cover topics such as supporting business continuity, repositioning quality as a strategic growth engine, and implementing strategies to improve supplier collaboration.
The event is complimentary for Veeva customers and quality, regulatory, legal and IT professionals. Learn more, register, and view the full Summit agenda at industries.veeva.com/Summit.
About Veeva for Cosmetics, Consumer Goods, and Chemical Industries
Founded in 2007, Veeva Systems is a global provider of cloud-based software solutions. We help quality, regulatory and commercial teams in the cosmetics, consumer goods, and chemical industries unify disconnected processes, documents and data. In doing so, we help our customers eliminate inefficiencies so they can bring innovative, high-quality products to market faster without compromising compliance. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. Learn more at industries.veeva.com.
For more information about Veeva’s solutions for the global life sciences industry and the more than 875 customers it serves, ranging from the world's largest pharmaceutical companies to emerging biotechs, visit veeva.com/eu.
Additional Information
Learn more about Veeva solutions for consumer goods, chemical, and cosmetics industries: www.industries.veeva.com
Connect with Veeva on LinkedIn: https://www.linkedin.com/showcase/qualityone/
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005531/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release
Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom